- Home
- FINW vs IMAB Comparison
FINW vs IMAB Comparison
Compare FINW & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- IMAB
- Stock Information
- Founded
- FINW 1999
- IMAB 2014
- Country
- FINW United States
- IMAB United States
- Employees
- FINW N/A
- IMAB N/A
- Industry
- FINW Commercial Banks
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- IMAB Health Care
- Exchange
- FINW Nasdaq
- IMAB Nasdaq
- Market Cap
- FINW 207.1M
- IMAB 200.9M
- IPO Year
- FINW 2021
- IMAB 2020
- Fundamental
- Price
- FINW $17.29
- IMAB $2.11
- Analyst Decision
- FINW Buy
- IMAB Strong Buy
- Analyst Count
- FINW 4
- IMAB 3
- Target Price
- FINW $20.75
- IMAB $6.33
- AVG Volume (30 Days)
- FINW 73.3K
- IMAB 392.1K
- Earning Date
- FINW 07-24-2025
- IMAB 05-15-2025
- Dividend Yield
- FINW N/A
- IMAB N/A
- EPS Growth
- FINW N/A
- IMAB N/A
- EPS
- FINW 0.96
- IMAB N/A
- Revenue
- FINW $75,327,000.00
- IMAB N/A
- Revenue This Year
- FINW $37.77
- IMAB N/A
- Revenue Next Year
- FINW $23.58
- IMAB N/A
- P/E Ratio
- FINW $18.00
- IMAB N/A
- Revenue Growth
- FINW 11.23
- IMAB N/A
- 52 Week Low
- FINW $11.31
- IMAB $0.60
- 52 Week High
- FINW $20.94
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- FINW 71.02
- IMAB 49.47
- Support Level
- FINW $15.57
- IMAB $2.01
- Resistance Level
- FINW $16.19
- IMAB $2.25
- Average True Range (ATR)
- FINW 0.60
- IMAB 0.13
- MACD
- FINW 0.09
- IMAB -0.03
- Stochastic Oscillator
- FINW 97.39
- IMAB 25.00
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).